Overall rank by patents
#36,685
Across all tracked assignees
USPTO PatentsView assignee record - 7 granted patents across 6 technology areas, active 2016–2024. Filing-trend and competitive-moat analysis cross-referenced to USPTO Patent Public Search. Primary class: A61P (SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS).
The verdict
National holds 7 US patents across 6 technology areas, rank #36,685 of 50,000 tracked assignees.
National Institute Of Immunology has been granted 7 US utility patents between 2016 and 2024, placing National Institute Of Immunology at rank #36,685 across all assignees tracked by PlainPatent. This portfolio spans 6 distinct Cooperative Patent Classification (CPC) subclasses, averaging 10.3 claims per patent with primary concentration in A61P (SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS). As a Foreign Corporation, National Institute Of Immunology is one of the more focused assignees in the PatentsView dataset. By volume, National sits between Nanoco 2D Materials Limited (7 patents, rank #36,681) and Natural Power Concepts, Inc. (7 patents, rank #36,689) - the closest US assignees by grant volume. The composite Innovation Score of 42.0/100 blends portfolio volume, filing velocity, technology breadth, and claim depth into a single comparable measure drawn directly from USPTO PatentsView records.
Filing cadence tells the strategic story. Between 2020 and 2025 the company received 4 grants, compared with 3 in the 2015–2019 window, a +33% shift in five-year velocity. Steady filing volume suggests sustained innovation without dramatic pivots. The Foreign Corporation classification further shapes interpretation, since corporate, government, and individual filers pursue patents for materially different reasons.
Claim depth and technology breadth together indicate competitive posture. National Institute Of Immunology's 10.3 average claims per patent suggests focused, narrowly drawn claims typical of single-invention filings, while concentration in 6 subclasses points to a focused technical program. Combined with portfolio volume, these signals let analysts, investors, and licensing professionals benchmark National Institute Of Immunology against peers pursuing similar technology classes.
Granted US patents 2015–2025 versus its nearest-ranked assignees by volume, this company marked ◀
Nanoco 2D Materials Limited
7 patents
Nanoscale Components, Inc.
7 patents
Nanoscribe Holding GmbH
7 patents
National Boss Hog Energy Services, LLC
7 patents
National Institute of Metrology
7 patents
National Molding LLC
7 patents
National and Kapodistrian University of Athens
7 patents
Natural Power Concepts, Inc.
7 patents
National Institute of Immunology
7 patents
What this shows National holds 7 patents at rank #36,685, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.
By rank, the assignees closest to #36,685 in granted patent volume.
Other assignees with the most granted patents in National's primary technology class.
National's Innovation Score vs. every tracked assignee
Composite of portfolio volume, filing velocity, technology breadth, and claim depth (0–100)
42 Top 32% higher than 68% of 50,000 US assignees
Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.
Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025
Teal-shaded recent years (2020–present) versus the 2016–2019 baseline. Full figures in the table below.
| Year | Patents Granted | Share of Period |
|---|---|---|
| 2016 | 1 | 14.3% |
| 2017 | 1 | 14.3% |
| 2019 | 1 | 14.3% |
| 2022 | 2 | 28.6% |
| 2023 | 1 | 14.3% |
| 2024 | 1 | 14.3% |
Top 6 of 6 technology areas
Overall rank by patents
#36,685
Across all tracked assignees
42.0 out of 100
How to use this portfolio
National's 7 grants land it in the top 32% by Innovation Score, but volume alone doesn't tell you where the strength sits.
Patent counts and the Innovation Score measure patenting activity, not commercial success or the legal strength of any patent. Many patents are filed defensively. Verify the status of an individual patent against official USPTO records.
Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.